These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 27525576)

  • 1. Safety of Immediate-Release Nifedipine.
    Means L; Benken ST; Tesoro EP
    J Cardiovasc Pharmacol; 2016 Nov; 68(5):395-399. PubMed ID: 27525576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the safety of short-acting nifedipine in children with hypertension.
    Egger DW; Deming DD; Hamada N; Perkin RM; Sahney S
    Pediatr Nephrol; 2002 Jan; 17(1):35-40. PubMed ID: 11793132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of long-acting dihydropyridine calcium channel blockers in hypertensive patients.
    Kloner RA; Vetrovec GW; Materson BJ; Levenstein M
    Am J Cardiol; 1998 Jan; 81(2):163-9. PubMed ID: 9591899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Another report of adverse reactions to immediate-release nifedipine.
    Fami MJ; Ho NT; Mason CM
    Pharmacotherapy; 1998; 18(5):1133-5. PubMed ID: 9758326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of sublingual nifedipine: a continuing concern.
    Messerli FH; Grossman E
    Arch Intern Med; 1999 Oct; 159(19):2259-60. PubMed ID: 10547164
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical features and up-to-date therapy of hypertensive emergencies].
    Meyer FP
    Dtsch Med Wochenschr; 2004 Apr; 129(14):768; author reply 768-9. PubMed ID: 15042498
    [No Abstract]   [Full Text] [Related]  

  • 7. Controlled release nifedipine and valsartan combination therapy in patients with essential hypertension: the adalat CR and valsartan cost-effectiveness combination (ADVANCE-combi) study.
    Saito I; Saruta T;
    Hypertens Res; 2006 Oct; 29(10):789-96. PubMed ID: 17283866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Echocardiographic predictors of an adverse response to a nifedipine trial in primary pulmonary hypertension: diminished left ventricular size and leftward ventricular septal bowing.
    Ricciardi MJ; Bossone E; Bach DS; Armstrong WF; Rubenfire M
    Chest; 1999 Nov; 116(5):1218-23. PubMed ID: 10559078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nifedipine and mortality. Grave defects in the dossier.
    Opie LH; Messerli FH
    Circulation; 1995 Sep; 92(5):1068-73. PubMed ID: 7648646
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy and adverse event of nifedipine sustained-release tablets for cyclosporin A-induced hypertension in patients with psoriasis.
    Nakayama J; Koga T; Furue M
    Eur J Dermatol; 1998 Dec; 8(8):563-8. PubMed ID: 9889429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypotension and coronary events on nifedipine: reassessing nifedipine safety.
    Prescrire Int; 1998 Jun; 7(35):90-1. PubMed ID: 10342928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety and use of short-acting nifedipine in hospitalized hypertensive children.
    Yiu V; Orrbine E; Rosychuk RJ; MacLaine P; Goodyer P; Girardin C; Gowrishankar M; Ogborn M; Midgley J; Filler G; Harley F
    Pediatr Nephrol; 2004 Jun; 19(6):644-50. PubMed ID: 15054645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease.
    Furberg CD; Psaty BM; Meyer JV
    Circulation; 1995 Sep; 92(5):1326-31. PubMed ID: 7648682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
    Brown MJ; Palmer CR; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
    Lancet; 2000 Jul; 356(9227):366-72. PubMed ID: 10972368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ventricular arrhythmia following short-acting nifedipine administration.
    Castaneda MP; Walsh CA; Woroniecki RP; Del Rio M; Flynn JT
    Pediatr Nephrol; 2005 Jul; 20(7):1000-2. PubMed ID: 15880273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Am J Hypertens; 2008 Aug; 21(8):948-54. PubMed ID: 18600215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
    Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
    Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Immediate-Release Nifedipine in Critically Ill Patients.
    Seto SL; Barra ME; Hamidi A; Sin JH; Devine LT
    J Pharm Pract; 2023 Jun; 36(3):614-619. PubMed ID: 35152786
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of perioperative myocardial protection with nifedipine versus nifedipine and metoprolol in patients undergoing elective coronary artery bypass grafting.
    Podesser BK; Schwarzacher S; Zwoelfer W; Binder TM; Wolner E; Seitelberger R
    J Thorac Cardiovasc Surg; 1995 Nov; 110(5):1461-9. PubMed ID: 7475198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose- and administration time-dependent effects of nifedipine gits on ambulatory blood pressure in hypertensive subjects.
    Hermida RC; Calvo C; Ayala DE; López JE; Rodríguez M; Chayán L; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2007; 24(3):471-93. PubMed ID: 17612946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.